ORPP logo
Image from Google Jackets

Bladder Cancer : Diagnosis and Clinical Management.

By: Contributor(s): Material type: TextTextPublisher: Newark : John Wiley & Sons, Incorporated, 2015Copyright date: ©2015Edition: 1st edDescription: 1 online resource (445 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781118674857
Subject(s): Genre/Form: Additional physical formats: Print version:: Bladder CancerDDC classification:
  • 616.99462
LOC classification:
  • RC280.B5 -- .B533 2015eb
Online resources:
Contents:
Intro -- Title Page -- Copyright Page -- Contents -- List of contributors -- Preface -- Acknowledgments -- Part I Diagnosis and treatment of non-muscle-invasive bladder cancer -- Chapter 1 Pathology -- Benign urothelium -- Reactive urothelium -- Urothelial hyperplasia -- Urothelial dysplasia -- Flat urothelial carcinoma in situ (CIS) -- Papillary lesions -- Invasive urothelial carcinoma -- Carcinomas with divergent (aberrant) differentiation -- Squamous cell carcinoma -- Adenocarcinoma -- Small cell/neuroendocrine carcinoma -- Nested variant of urothelial carcinoma -- Lymphoepithelioma-like carcinoma -- Micropapillary carcinoma -- Sarcomatoid carcinoma -- Useful web links -- References -- Chapter 2 Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder -- Introduction -- Risk stratification -- Ta high-grade urothelial carcinoma of the bladder -- Carcinoma in situ -- T1 urothelial carcinoma of the bladder -- Non-surgical treatment options for BCG failure -- Early radical cystectomy -- References -- Chapter 3 Utility of urine biomarkers -- Introduction -- FDA-approved urine markers -- Useful web links -- Note -- References -- Chapter 4 Novel endoscopic techniques for the detection of bladder cancer -- Photodynamic diagnosis (PDD) -- Narrow band imaging -- Confocal laser endomicroscopy -- Optical coherence tomography -- Conclusions -- Useful web link -- References -- Chapter 5 Transurethral resection of bladder tumors -- Introduction -- Endoscopy and visualization of the bladder -- The first TURBT and the evolution of instrumentation -- Patient preparation -- Surgical technique -- Special situations for TURBT -- Efficacy of TURBT -- Other techniques -- Intravesical therapy -- Radical TURBT and bladder-sparing for muscle-invasive disease -- Conclusions -- Useful web links -- References.
Chapter 6 Intravesical chemotherapy -- Introduction -- History of intravesical chemotherapy -- Intravesical chemotherapy -- Treatment outcome -- Complications/side effects -- Device-assisted intravesical chemotherapy -- Useful web links -- Note -- References -- Chapter 7 Intravesical immunotherapy -- Introduction -- History/development -- BCG mechanism of action -- Induction -- BCG and carcinoma in situ -- BCG prevention of recurrence -- BCG prevention of progression -- BCG maintenance -- BCG toxicity and treatment -- Alternative forms of immunotherapy -- Conclusion -- Useful web links -- References -- Chapter 8 HGT1 bladder cancer: Diagnosis and treatment -- Overview -- Diagnosis -- Follow-up -- Treatment -- Useful web links -- References -- Chapter 9 What to do when bacillus Calmette-Guérin fails -- Introduction -- Definition of BCG failure -- Treatment of BCG-refractory CIS -- Conclusion -- Useful web links -- References -- Part II T2-4 -- Chapter 10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction -- Introduction -- Patient selection -- Pre-operative preparation -- Inpatient standardization and pathways (inpatient and beyond) -- Conclusions and future state - what do we need to work on? -- Useful web links -- References -- Chapter 11 Radical cystectomy: Techniques and outcomes -- Introduction -- Anatomy -- Diagnosis and staging -- Indications and treatment -- Perioperative management -- Post-operative management -- Pain management -- Discharge and post-operative care -- Extent of lymph node dissection -- Technique: radical cystectomy with extended pelvic lymph node dissection -- Outcomes -- Complications -- Conclusion -- Useful web link -- References -- Chapter 12 Cystectomy in the female patient -- Introduction -- Anterior exenteration and pelvic lymphadenectomy.
Surgical considerations in pre-operative planning of orthotopic diversions in female patients -- Functional aspects of orthotopic neobladder reconstruction in female patients -- Technique of anterior exenteration -- Risk of cancer recurrence in the urethra in women -- Incontinence, residual urine, and urinary retention after orthotopic neobladder reconstruction -- Follow-up of women with ileal neobladder placement -- Useful web links -- References -- Chapter 13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes -- Operative outcomes -- Post-operative outcomes -- Complications -- Oncologic outcomes -- Functional outcomes -- Useful web links -- References -- Chapter 14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials -- Oncologic outcomes -- Surgical margin status -- Lymph node dissection -- Complications -- Randomized studies -- Conclusions -- Useful web links -- References -- Chapter 15 Role of extended lymphadenectomy -- The role of extended lymphadenectomy -- Lymphatic drainage of the bladder - historical and anatomic considerations -- Prognostic importance of lymph node status -- Extent of lymphadenectomy -- Outcomes based on the extent of lymphadenectomy -- Ongoing randomized studies evaluating the extent of lymphadenectomy -- Conclusions -- References -- Chapter 16 Management of the urethra in the cystectomy patient -- Introduction -- Incidence of urethral cancer following radical cystectomy -- Impact of urinary diversion type on metachronous urethral cancers -- Post radical cystectomy monitoring of the urethra -- Treatment for cancer of the retained urethra -- Conclusion -- Useful web links -- References -- Chapter 17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder -- Introduction.
Pre-surgical versus neoadjuvant chemotherapy -- Outcomes of surgical consolidation after systemic chemotherapy -- Adjuvant radiation therapy -- Proposed clinical algorithm -- Conclusion -- Useful web links -- References -- Part III Primary bladder-sparing therapy -- Chapter 18 Radical transurethral resection -- Introduction -- Radical TURBT -- Prospective studies: inclusion criteria -- Prospective studies: results -- Candidates for TURBT -- TURBT as a prognostic factor -- TURBT and neoadjuvant chemotherapy -- Follow-up of patients treated with TURBT -- Summary -- Useful web links -- References -- Chapter 19 Partial cystectomy -- Introduction -- Indications -- Cancer in bladder diverticulum -- Adenocarcinoma and urachal tumors -- Other non-urothelial tumors -- Pre-operative considerations -- Surgical technique -- Perioperative complications -- Follow-up and outcomes -- Useful web links -- References -- Chapter 20 Integrating chemotherapy and radiotherapy for bladder cancer -- Introduction -- Selecting candidates for bladder-sparing therapy -- Chemotherapy concurrent with radiation therapy -- Neoadjuvant and adjuvant chemotherapy -- Local failure and salvage cystectomy -- Quality of life after bladder-sparing therapy -- Outcomes of bladder-sparing therapy -- The role for chemoradiation in non-muscle-invasive disease -- Future advances -- Conclusion -- Useful web links -- References -- Part IV Urinary tract reconstruction -- Chapter 21 Orthotopic neobladder -- Introduction -- Patient selection -- Basic tenets of pouch construction -- Surgical techniques for orthotopic diversion -- Results -- Conclusion -- Useful web links -- References -- Chapter 22 Continent cutaneous diversion -- General considerations about the choice of the type of continent urinary diversion -- Surgical techniques -- Ureteral implantation -- Complications -- Summary.
Useful web links -- References -- Chapter 23 Non-continent urinary diversion -- Introduction -- Patient preparation -- Surgical techniques -- Complications -- Quality of life (QoL) -- Follow-up of patients with conduit diversion -- Conclusions -- Useful Web links -- References -- Part V Treatment of regionally advanced and metastatic bladder cancer -- Chapter 24 Molecular determinants of chemotherapy response -- Introduction -- Potential biomarkers predicting response to chemotherapy - DNA repair enzymes, drug efflux proteins, and p53 -- Germline pharmacogenomics -- Gene expression models in urothelial cancer -- Conclusion -- References -- Chapter 25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer -- Introduction -- Cystectomy and chemoradiation series -- Rationale for chemotherapy prior to definitive surgery or chemoradiation therapy -- Randomized trials of neoadjuvant chemotherapy: data support a survival benefit -- Meta-analyses -- Barriers to implementation of neoadjuvant chemotherapy for bladder cancer -- Novel combinations of neoadjuvant therapy for bladder cancer -- Developing personalized neoadjuvant therapy: a paradigm to define risk of relapse and response to systemic therapy -- Summary -- Useful web links -- References -- Chapter 26 Adjuvant chemotherapy for invasive bladder cancer -- Introduction -- Adjuvant treatment -- Evidence summary -- Molecular biology and targeted therapies -- Conclusions and future directions -- Useful web links -- References -- Chapter 27 Treatment of metastatic bladder cancer -- Non-cisplatin-containing chemotherapy regimens -- Prognostic and predictive biomarkers in metastatic UC -- Second-line therapy -- Useful web links -- References -- Chapter 28 Treatment of poor risk patients -- Introduction -- What is poor risk urothelial cancer? -- Treatment of poor risk patients.
Conclusions.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Intro -- Title Page -- Copyright Page -- Contents -- List of contributors -- Preface -- Acknowledgments -- Part I Diagnosis and treatment of non-muscle-invasive bladder cancer -- Chapter 1 Pathology -- Benign urothelium -- Reactive urothelium -- Urothelial hyperplasia -- Urothelial dysplasia -- Flat urothelial carcinoma in situ (CIS) -- Papillary lesions -- Invasive urothelial carcinoma -- Carcinomas with divergent (aberrant) differentiation -- Squamous cell carcinoma -- Adenocarcinoma -- Small cell/neuroendocrine carcinoma -- Nested variant of urothelial carcinoma -- Lymphoepithelioma-like carcinoma -- Micropapillary carcinoma -- Sarcomatoid carcinoma -- Useful web links -- References -- Chapter 2 Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder -- Introduction -- Risk stratification -- Ta high-grade urothelial carcinoma of the bladder -- Carcinoma in situ -- T1 urothelial carcinoma of the bladder -- Non-surgical treatment options for BCG failure -- Early radical cystectomy -- References -- Chapter 3 Utility of urine biomarkers -- Introduction -- FDA-approved urine markers -- Useful web links -- Note -- References -- Chapter 4 Novel endoscopic techniques for the detection of bladder cancer -- Photodynamic diagnosis (PDD) -- Narrow band imaging -- Confocal laser endomicroscopy -- Optical coherence tomography -- Conclusions -- Useful web link -- References -- Chapter 5 Transurethral resection of bladder tumors -- Introduction -- Endoscopy and visualization of the bladder -- The first TURBT and the evolution of instrumentation -- Patient preparation -- Surgical technique -- Special situations for TURBT -- Efficacy of TURBT -- Other techniques -- Intravesical therapy -- Radical TURBT and bladder-sparing for muscle-invasive disease -- Conclusions -- Useful web links -- References.

Chapter 6 Intravesical chemotherapy -- Introduction -- History of intravesical chemotherapy -- Intravesical chemotherapy -- Treatment outcome -- Complications/side effects -- Device-assisted intravesical chemotherapy -- Useful web links -- Note -- References -- Chapter 7 Intravesical immunotherapy -- Introduction -- History/development -- BCG mechanism of action -- Induction -- BCG and carcinoma in situ -- BCG prevention of recurrence -- BCG prevention of progression -- BCG maintenance -- BCG toxicity and treatment -- Alternative forms of immunotherapy -- Conclusion -- Useful web links -- References -- Chapter 8 HGT1 bladder cancer: Diagnosis and treatment -- Overview -- Diagnosis -- Follow-up -- Treatment -- Useful web links -- References -- Chapter 9 What to do when bacillus Calmette-Guérin fails -- Introduction -- Definition of BCG failure -- Treatment of BCG-refractory CIS -- Conclusion -- Useful web links -- References -- Part II T2-4 -- Chapter 10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction -- Introduction -- Patient selection -- Pre-operative preparation -- Inpatient standardization and pathways (inpatient and beyond) -- Conclusions and future state - what do we need to work on? -- Useful web links -- References -- Chapter 11 Radical cystectomy: Techniques and outcomes -- Introduction -- Anatomy -- Diagnosis and staging -- Indications and treatment -- Perioperative management -- Post-operative management -- Pain management -- Discharge and post-operative care -- Extent of lymph node dissection -- Technique: radical cystectomy with extended pelvic lymph node dissection -- Outcomes -- Complications -- Conclusion -- Useful web link -- References -- Chapter 12 Cystectomy in the female patient -- Introduction -- Anterior exenteration and pelvic lymphadenectomy.

Surgical considerations in pre-operative planning of orthotopic diversions in female patients -- Functional aspects of orthotopic neobladder reconstruction in female patients -- Technique of anterior exenteration -- Risk of cancer recurrence in the urethra in women -- Incontinence, residual urine, and urinary retention after orthotopic neobladder reconstruction -- Follow-up of women with ileal neobladder placement -- Useful web links -- References -- Chapter 13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes -- Operative outcomes -- Post-operative outcomes -- Complications -- Oncologic outcomes -- Functional outcomes -- Useful web links -- References -- Chapter 14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials -- Oncologic outcomes -- Surgical margin status -- Lymph node dissection -- Complications -- Randomized studies -- Conclusions -- Useful web links -- References -- Chapter 15 Role of extended lymphadenectomy -- The role of extended lymphadenectomy -- Lymphatic drainage of the bladder - historical and anatomic considerations -- Prognostic importance of lymph node status -- Extent of lymphadenectomy -- Outcomes based on the extent of lymphadenectomy -- Ongoing randomized studies evaluating the extent of lymphadenectomy -- Conclusions -- References -- Chapter 16 Management of the urethra in the cystectomy patient -- Introduction -- Incidence of urethral cancer following radical cystectomy -- Impact of urinary diversion type on metachronous urethral cancers -- Post radical cystectomy monitoring of the urethra -- Treatment for cancer of the retained urethra -- Conclusion -- Useful web links -- References -- Chapter 17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder -- Introduction.

Pre-surgical versus neoadjuvant chemotherapy -- Outcomes of surgical consolidation after systemic chemotherapy -- Adjuvant radiation therapy -- Proposed clinical algorithm -- Conclusion -- Useful web links -- References -- Part III Primary bladder-sparing therapy -- Chapter 18 Radical transurethral resection -- Introduction -- Radical TURBT -- Prospective studies: inclusion criteria -- Prospective studies: results -- Candidates for TURBT -- TURBT as a prognostic factor -- TURBT and neoadjuvant chemotherapy -- Follow-up of patients treated with TURBT -- Summary -- Useful web links -- References -- Chapter 19 Partial cystectomy -- Introduction -- Indications -- Cancer in bladder diverticulum -- Adenocarcinoma and urachal tumors -- Other non-urothelial tumors -- Pre-operative considerations -- Surgical technique -- Perioperative complications -- Follow-up and outcomes -- Useful web links -- References -- Chapter 20 Integrating chemotherapy and radiotherapy for bladder cancer -- Introduction -- Selecting candidates for bladder-sparing therapy -- Chemotherapy concurrent with radiation therapy -- Neoadjuvant and adjuvant chemotherapy -- Local failure and salvage cystectomy -- Quality of life after bladder-sparing therapy -- Outcomes of bladder-sparing therapy -- The role for chemoradiation in non-muscle-invasive disease -- Future advances -- Conclusion -- Useful web links -- References -- Part IV Urinary tract reconstruction -- Chapter 21 Orthotopic neobladder -- Introduction -- Patient selection -- Basic tenets of pouch construction -- Surgical techniques for orthotopic diversion -- Results -- Conclusion -- Useful web links -- References -- Chapter 22 Continent cutaneous diversion -- General considerations about the choice of the type of continent urinary diversion -- Surgical techniques -- Ureteral implantation -- Complications -- Summary.

Useful web links -- References -- Chapter 23 Non-continent urinary diversion -- Introduction -- Patient preparation -- Surgical techniques -- Complications -- Quality of life (QoL) -- Follow-up of patients with conduit diversion -- Conclusions -- Useful Web links -- References -- Part V Treatment of regionally advanced and metastatic bladder cancer -- Chapter 24 Molecular determinants of chemotherapy response -- Introduction -- Potential biomarkers predicting response to chemotherapy - DNA repair enzymes, drug efflux proteins, and p53 -- Germline pharmacogenomics -- Gene expression models in urothelial cancer -- Conclusion -- References -- Chapter 25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer -- Introduction -- Cystectomy and chemoradiation series -- Rationale for chemotherapy prior to definitive surgery or chemoradiation therapy -- Randomized trials of neoadjuvant chemotherapy: data support a survival benefit -- Meta-analyses -- Barriers to implementation of neoadjuvant chemotherapy for bladder cancer -- Novel combinations of neoadjuvant therapy for bladder cancer -- Developing personalized neoadjuvant therapy: a paradigm to define risk of relapse and response to systemic therapy -- Summary -- Useful web links -- References -- Chapter 26 Adjuvant chemotherapy for invasive bladder cancer -- Introduction -- Adjuvant treatment -- Evidence summary -- Molecular biology and targeted therapies -- Conclusions and future directions -- Useful web links -- References -- Chapter 27 Treatment of metastatic bladder cancer -- Non-cisplatin-containing chemotherapy regimens -- Prognostic and predictive biomarkers in metastatic UC -- Second-line therapy -- Useful web links -- References -- Chapter 28 Treatment of poor risk patients -- Introduction -- What is poor risk urothelial cancer? -- Treatment of poor risk patients.

Conclusions.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.